This newspaper article presents an overview of genetic testing for common diseases, an important development in clinical medicine and one likely to increase rapidly in importance. It does a good job of providing lists and bullet points that help people understand key considerations.
But the story falls short of best practices in several important ways.
Essentially the article provides a one-sided view of genetic testing, with the addition of some useful consumer information provided by the practitioners themselves. For such an important topic about critical health decisions, readers deserve a well-balanced story.
The article fails to state how much these tests cost, a serious shortcoming in a story like this.
It makes generalizations about testing being covered by private insurance and Medicare, but this creates a false impression. Testing is often covered only for certain conditions and under specified circumstances.
The story does not attempt to quantify the benefits of testing and treatment based on the tests. For instance, it would be very interesting to know whether research has established reduced mortality or morbidity in patients who have had the testing and treatment compared to a control group.
The article states that results need to be interpreted carefully and rationally.
But it fails to address two specific potential harms in a substantial way:
The article provides no evidence to verify the claims about the accuracy and benefit of the tests.
The article refrains from exaggerating the prevalence or severity of the diseases for which genetic testing is available.
Sourcing for this story is inadequate. It does not provide a range of views and proper context.
What’s clearly missing are the perspectives of dispassionate sources–clinicians and researchers who can talk about the value of these tests more generally. Information from sources who can describe poor outcomes (excessive anxiety, emotionally-driven decisions, false positives, inappropriate testing and serious treatment side effects) would have been particularly useful.
The story fails to mention the options facing those who choose not to be tested or who are tested but prefer to choose less invasive responses: lifestyle changes, medication (the birth control pill, for example, to reduce ovarian cancer risk) and close monitoring.
The choice is often testing vs. interventions to reduce risk, or testing plus treatment vs. testing with other interventions. This is not adequately explained.
This story is minimally satisfactory under this criterion. It provides a link to a source where to find a genetic counselor in your area.
But the article should have spelled out whether these services are widely available, only in large teaching hospitals, specialty clinics, etc.
The story correctly describes the testing as well-established but quickly developing as research into the links between specific genes and conditions continues.
There does not appear to be a press release that may have triggered the article.
Systematic, Criteria-Driven
Take all the issues enmeshed in any cancer screening story and amplify it with the liquid biopsy issue. @AP's @CarlaKJohnson. did a solid job here. https://apnews.com/article/science-business-health-hodgkin-lymphoma-oregon-ca899bb9c4c7f1859d4e9ce16a1cf78d
Come on, NY Times; you must do better than this. Important research doesn’t need hype and the “breaking news” BS doesn’t help readers or patients. https://www.healthnewsreview.org/2022/03/nyt-proclaims-breaking-news/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like